Oral components
The composition addresses the challenge of dissolving and stabilizing β-glycyrrhetinic acid in oral compositions by incorporating β-glycyrrhetinic acid, a nonionic surfactant, and a polyhydric alcohol, specifically using polyoxyethylene hydrogenated castor oil and a pH of 6.0 or higher, to suppress precipitation and ensure long-term efficacy.
JP2026110409APending Publication Date: 2026-07-02SUNSTAR INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- SUNSTAR INC
- Filing Date
- 2024-12-20
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
Existing oral compositions struggle to dissolve and stabilize β-glycyrrhetinic acid effectively due to its insolubility in water, necessitating a stable blending method for large amounts.
Method used
An oral composition comprising β-glycyrrhetinic acid, a nonionic surfactant, and a polyhydric alcohol, specifically using polyoxyethylene hydrogenated castor oil and a pH of 6.0 or higher, to suppress precipitation and ensure long-term stability.
Benefits of technology
The composition enables clear dissolution and stable long-term containment of β-glycyrrhetinic acid, enhancing its anti-inflammatory effect.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026110409000001
Abstract
Regarding oral compositions, β-glycyrrhetinic acid is dissolved in a clear solution and stabilized over a long period of time. [Solution] The oral composition contains β-glycyrrhetinic acid, a nonionic surfactant, and a polyhydric alcohol.
Need to check novelty before this filing date? Find Prior Art